CAS 1031206-36-6

Fórmula: C18H16O4

InChI: InChI=1S/C18H16O4/c1-11-3-5-16-14(7-11)18(20)13(10-22-16)8-12-4-6-17(21-2)15(19)9-12/h3-9,19H,10H2,1-2H3/b13-8+

Chave InChI: BZCADTHMZLYKAR-MDWZMJQESA-N

SMILES: CC1=CC2=C(C=C1)OC/C(=C\C3=CC(=C(C=C3)OC)O)/C2=O

(3E)-2,3-Dihydro-3-[(3-Hydroxy-4-Methoxyphenyl)Methylene]-6-Methyl-4H-1-Benzopyran-4-One

CAS: 1031206-36-6

(3E)-2,3-Dihydro-3-[(3-Hydroxy-4-Methoxyphenyl)Methylene]-6-Methyl-4H-1-Benzopyran-4-One

Fórmula: C₁₈H₁₆O₄

Pureza: 0.97

Peso molecular: 296.32

Ref: 54-OR1024162

IMS2186

CAS: 1031206-36-6

IMS2186: antichoroidal neovascularization reagent, arrests G2/M cancer phase, anti-proliferative, reduces eye leakage, non-toxic.

Fórmula: C₁₈H₁₆O₄

Pureza: 99.96%

Cor e Forma: Solid

Peso molecular: 296.3172

Ref: TM-T67746

IMS2186

CAS: 1031206-36-6

IMS2186

Fórmula: C₁₈H₁₆O₄

Pureza: ≥98%

Peso molecular: 296.32

Ref: 54-BUP13519

IMS2186

CAS: 1031206-36-6

Fórmula: C₁₈H₁₆O₄

Pureza: 98%

Cor e Forma: Solid

Peso molecular: 296.3172

Ref: IN-DA0097FJ

IMS2186

CAS: 1031206-36-6

IMS2186 is a small molecule drug that inhibits the proliferation of cells and has an inhibitory effect on angiogenesis in vivo. This drug is also effective against inflammatory diseases, such as psoriasis and rheumatoid arthritis. IMS2186 has been shown to have a molecular pathogenesis of proliferative diabetic retinopathy. It inhibits the production of pro-inflammatory cytokines, growth factors, and pro-angiogenic proteins by targeting the cellular nucleus. IMS2186 may be able to prevent cancer cell growth and choroidal neovascularization in patients with age-related macular degeneration.

Fórmula: C₁₈H₁₆O₄

Pureza: Min. 95%

Peso molecular: 296.32 g/mol

Ref: 3D-GRB20636